Share Price and Basic Stock Data
Last Updated: November 22, 2025, 10:46 am
| PEG Ratio | -29.14 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Bayer CropScience Ltd operates in the agrochemical sector, focusing on crop protection products and solutions. As of the latest reporting, the company’s share price stood at ₹4,576, with a market capitalization of ₹20,562 Cr. The firm reported total sales of ₹5,140 Cr for the fiscal year ending March 2023, which reflects a modest increase from ₹4,734 Cr in the previous fiscal year. This upward trajectory continued with a trailing twelve-month (TTM) revenue of ₹5,572 Cr. Quarterly sales exhibited fluctuations, with a peak of ₹1,740 Cr recorded in June 2023, followed by a decline to ₹1,617 Cr in September 2023. The company’s ability to navigate the seasonal nature of the agrochemical market is noteworthy, as evidenced by a rebound in sales to ₹1,915 Cr in June 2025. Overall, Bayer CropScience’s revenue trends indicate resilience in a competitive landscape, supported by its extensive product portfolio and market presence.
Profitability and Efficiency Metrics
Bayer CropScience’s profitability metrics illustrate a solid performance, with a reported net profit of ₹609 Cr for the fiscal year ending March 2025. This is a decline from ₹758 Cr in the prior year, indicating some challenges in maintaining profitability amidst rising costs. The operating profit margin (OPM) for the same period stood at 13%, reflecting a decrease from 17% in the previous year. However, the company maintained an impressive return on equity (ROE) of 20.0% and a return on capital employed (ROCE) of 24.8%, both of which are above average compared to industry standards. The interest coverage ratio (ICR) of 47.61x underscores the company’s strong capability to meet its interest obligations, indicating a sound financial structure. These metrics reveal that while Bayer CropScience faces certain profitability pressures, its operational efficiency and return ratios remain robust.
Balance Sheet Strength and Financial Ratios
Bayer CropScience’s balance sheet reflects a strong financial position, with no reported borrowings, indicating a debt-free status that enhances its financial stability. The company boasts a price-to-book value (P/BV) ratio of 7.76x, suggesting a premium valuation compared to its book value of ₹634.83 per share as of March 2025. This high P/BV ratio may indicate investor confidence in the company’s growth prospects, despite the lack of reserves reported. The current ratio of 2.01 and quick ratio of 0.94 highlight a comfortable liquidity position, although the quick ratio suggests some reliance on inventory for short-term obligations. The cash conversion cycle (CCC) of 234 days indicates that the company takes a longer time to convert investments in inventory and accounts receivable into cash, which could be an area for operational improvement. Overall, Bayer CropScience’s balance sheet demonstrates resilience and strategic management of resources.
Shareholding Pattern and Investor Confidence
The shareholding structure of Bayer CropScience Ltd shows a strong promoter presence, with promoters holding 71.44% of the total shares as of March 2025. This significant stake indicates a high level of confidence from the promoters in the company’s long-term strategy. Foreign institutional investors (FIIs) accounted for 3.80% of the shareholding, while domestic institutional investors (DIIs) held 11.22%. The public shareholding stood at 13.56%, with the total number of shareholders increasing to 58,109, reflecting growing retail interest. Notably, the shareholding pattern has remained stable over recent quarters, suggesting consistent investor confidence. However, the relatively low percentage of FIIs may indicate limited international investor interest, which could impact the stock’s liquidity and market perception. Overall, Bayer CropScience’s shareholding structure signals a solid foundation of support, particularly from its promoters.
Outlook, Risks, and Final Insight
The outlook for Bayer CropScience remains cautiously optimistic, driven by its strong market position and operational efficiencies. However, the company faces several risks, including fluctuating raw material costs and regulatory challenges within the agrochemical sector. The decline in net profit from ₹758 Cr in the previous year to ₹609 Cr signals potential operational hurdles that may need addressing to sustain profitability. Additionally, Bayer CropScience’s longer cash conversion cycle of 234 days could constrain liquidity in times of market stress. The company’s ability to innovate and adapt to changing agricultural practices will be crucial for its future growth. Should Bayer CropScience effectively manage its cost structures and capitalize on emerging market opportunities, it could enhance its profitability and maintain investor confidence. On the flip side, persistent operational challenges could dampen its growth trajectory, necessitating close monitoring of performance metrics and market conditions.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Bayer CropScience Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Epigral Ltd | 6,258 Cr. | 1,452 | 2,196/1,440 | 15.6 | 487 | 0.41 % | 24.9 % | 22.3 % | 10.0 |
| Dharmaj Crop Guard Ltd | 860 Cr. | 253 | 391/165 | 17.7 | 131 | 0.00 % | 12.0 % | 9.28 % | 10.0 |
| Bhaskar Agrochemicals Ltd | 64.7 Cr. | 124 | 149/56.6 | 11.6 | 40.0 | 0.00 % | 21.3 % | 24.7 % | 10.0 |
| Bhagiradha Chemicals & Industries Ltd | 3,250 Cr. | 252 | 365/228 | 123 | 54.9 | 0.06 % | 7.44 % | 4.91 % | 1.00 |
| Best Agrolife Ltd | 710 Cr. | 300 | 670/244 | 55.5 | 342 | 1.00 % | 12.9 % | 9.95 % | 10.0 |
| Industry Average | 11,119.20 Cr | 1,490.43 | 32.33 | 472.46 | 0.45% | 15.21% | 19.87% | 7.25 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,667 | 1,452 | 1,038 | 982 | 1,740 | 1,617 | 955 | 792 | 1,631 | 1,738 | 1,057 | 1,046 | 1,915 |
| Expenses | 1,272 | 1,214 | 952 | 777 | 1,315 | 1,312 | 827 | 695 | 1,317 | 1,554 | 1,037 | 876 | 1,566 |
| Operating Profit | 395 | 238 | 85 | 206 | 425 | 305 | 128 | 97 | 314 | 184 | 20 | 171 | 348 |
| OPM % | 24% | 16% | 8% | 21% | 24% | 19% | 13% | 12% | 19% | 11% | 2% | 16% | 18% |
| Other Income | 14 | 14 | 116 | 24 | 21 | 16 | 15 | 29 | 27 | 24 | 32 | 37 | 19 |
| Interest | 4 | 8 | 3 | 7 | 8 | 4 | 3 | 5 | 4 | 3 | 4 | 6 | 5 |
| Depreciation | 23 | 15 | 14 | 27 | 31 | 12 | 15 | 16 | 22 | 14 | 15 | 34 | 27 |
| Profit before tax | 382 | 229 | 184 | 195 | 406 | 306 | 124 | 105 | 316 | 190 | 34 | 168 | 335 |
| Tax % | 21% | 29% | 27% | 19% | 19% | 27% | 25% | 9% | 20% | 28% | -2% | 15% | 17% |
| Net Profit | 303 | 163 | 134 | 158 | 328 | 223 | 93 | 96 | 254 | 136 | 34 | 143 | 279 |
| EPS in Rs | 67.33 | 36.18 | 29.93 | 35.27 | 73.09 | 49.60 | 20.72 | 21.36 | 56.56 | 30.33 | 7.61 | 31.89 | 62.01 |
Last Updated: August 19, 2025, 10:35 pm
Below is a detailed analysis of the quarterly data for Bayer CropScience Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,915.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,046.00 Cr. (Mar 2025) to 1,915.00 Cr., marking an increase of 869.00 Cr..
- For Expenses, as of Jun 2025, the value is 1,566.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 876.00 Cr. (Mar 2025) to 1,566.00 Cr., marking an increase of 690.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 348.00 Cr.. The value appears strong and on an upward trend. It has increased from 171.00 Cr. (Mar 2025) to 348.00 Cr., marking an increase of 177.00 Cr..
- For OPM %, as of Jun 2025, the value is 18.00%. The value appears strong and on an upward trend. It has increased from 16.00% (Mar 2025) to 18.00%, marking an increase of 2.00%.
- For Other Income, as of Jun 2025, the value is 19.00 Cr.. The value appears to be declining and may need further review. It has decreased from 37.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 18.00 Cr..
- For Interest, as of Jun 2025, the value is 5.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 6.00 Cr. (Mar 2025) to 5.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 27.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 34.00 Cr. (Mar 2025) to 27.00 Cr., marking a decrease of 7.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 335.00 Cr.. The value appears strong and on an upward trend. It has increased from 168.00 Cr. (Mar 2025) to 335.00 Cr., marking an increase of 167.00 Cr..
- For Tax %, as of Jun 2025, the value is 17.00%. The value appears to be increasing, which may not be favorable. It has increased from 15.00% (Mar 2025) to 17.00%, marking an increase of 2.00%.
- For Net Profit, as of Jun 2025, the value is 279.00 Cr.. The value appears strong and on an upward trend. It has increased from 143.00 Cr. (Mar 2025) to 279.00 Cr., marking an increase of 136.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 62.01. The value appears strong and on an upward trend. It has increased from 31.89 (Mar 2025) to 62.01, marking an increase of 30.12.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:49 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,188 | 3,660 | 2,769 | 2,803 | 2,710 | 3,167 | 3,609 | 4,261 | 4,734 | 5,140 | 5,106 | 5,473 | 5,572 |
| Expenses | 2,768 | 3,144 | 2,334 | 2,389 | 2,300 | 2,684 | 2,883 | 3,450 | 3,923 | 4,216 | 4,147 | 4,783 | 4,827 |
| Operating Profit | 419 | 516 | 435 | 414 | 410 | 483 | 726 | 812 | 812 | 924 | 959 | 691 | 745 |
| OPM % | 13% | 14% | 16% | 15% | 15% | 15% | 20% | 19% | 17% | 18% | 19% | 13% | 13% |
| Other Income | 91 | 88 | 82 | 70 | 39 | 51 | -64 | 69 | 112 | 168 | 76 | 118 | 102 |
| Interest | 5 | 5 | 10 | 7 | 11 | 10 | 14 | 13 | 13 | 22 | 20 | 17 | 18 |
| Depreciation | 65 | 25 | 25 | 29 | 33 | 44 | 65 | 74 | 64 | 80 | 74 | 85 | 91 |
| Profit before tax | 441 | 574 | 482 | 448 | 404 | 480 | 583 | 794 | 847 | 990 | 941 | 707 | 737 |
| Tax % | 34% | 33% | 35% | 35% | 26% | 30% | 19% | 38% | 24% | 23% | 21% | 20% | |
| Net Profit | 290 | 383 | 315 | 291 | 300 | 337 | 474 | 493 | 645 | 758 | 740 | 568 | 609 |
| EPS in Rs | 79.06 | 104.59 | 89.13 | 82.31 | 87.41 | 98.18 | 105.58 | 109.72 | 143.58 | 168.71 | 164.77 | 126.38 | 135.49 |
| Dividend Payout % | 7% | 20% | 19% | 21% | 21% | 18% | 24% | 105% | 104% | 77% | 85% | 99% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 32.07% | -17.75% | -7.62% | 3.09% | 12.33% | 40.65% | 4.01% | 30.83% | 17.52% | -2.37% | -23.24% |
| Change in YoY Net Profit Growth (%) | 0.00% | -49.82% | 10.14% | 10.71% | 9.24% | 28.32% | -36.64% | 26.82% | -13.31% | -19.89% | -20.87% |
Bayer CropScience Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 9% |
| 3 Years: | 5% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 0% |
| 3 Years: | -2% |
| TTM: | -11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | -3% |
| 3 Years: | -1% |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 23% |
| 3 Years: | 24% |
| Last Year: | 20% |
Last Updated: September 5, 2025, 2:36 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 47 | 57 | 53 | 72 | 89 | 81 | 73 | 65 | 77 | 69 | 69 | 63 |
| Inventory Days | 98 | 85 | 169 | 178 | 175 | 294 | 206 | 226 | 235 | 268 | 222 | 319 |
| Days Payable | 51 | 40 | 52 | 67 | 67 | 164 | 101 | 142 | 127 | 129 | 87 | 148 |
| Cash Conversion Cycle | 94 | 102 | 171 | 184 | 197 | 211 | 177 | 149 | 185 | 208 | 204 | 234 |
| Working Capital Days | 88 | 53 | 92 | 104 | 134 | 116 | 77 | 61 | 84 | 86 | 78 | 88 |
| ROCE % | 24% | 31% | 25% | 23% | 22% | 25% | 30% | 31% | 31% | 34% | 34% | 25% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Mirae Asset Large & Midcap Fund | 792,954 | 1.33 | 449.55 | 792,954 | 2025-04-22 17:25:13 | 0% |
| Nippon India Small Cap Fund | 531,460 | 0.65 | 301.3 | 531,460 | 2025-04-22 17:25:13 | 0% |
| Mirae Asset Midcap Fund | 510,084 | 1.99 | 289.18 | 510,084 | 2025-04-22 17:25:14 | 0% |
| Aditya Birla Sun Life ELSS Tax Saver Fund | 392,896 | 1.48 | 222.75 | 392,896 | 2025-04-22 17:25:14 | 0% |
| Aditya Birla Sun Life Frontline Equity Fund | 329,435 | 0.71 | 186.77 | 329,435 | 2025-04-22 17:25:14 | 0% |
| Nippon India Growth Fund | 303,512 | 0.7 | 172.07 | 303,512 | 2025-04-22 17:25:14 | 0% |
| HSBC Midcap Fund | 294,959 | 1.72 | 167.22 | 294,959 | 2025-04-22 17:25:14 | 0% |
| Aditya Birla Sun Life MNC Fund - Div | 280,976 | 4.49 | 159.3 | 280,976 | 2025-04-22 17:25:14 | 0% |
| Aditya Birla Sun Life MNC Fund - Gr | 280,976 | 4.49 | 159.3 | 280,976 | 2025-04-22 17:25:14 | 0% |
| Kotak Flexicap Fund - Regular Plan | 215,000 | 0.27 | 121.89 | 215,000 | 2025-04-22 14:53:35 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 126.38 | 164.77 | 168.71 | 143.58 | 109.72 |
| Diluted EPS (Rs.) | 126.38 | 164.77 | 168.71 | 143.58 | 109.72 |
| Cash EPS (Rs.) | 145.41 | 181.40 | 186.57 | 158.08 | 126.19 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 634.83 | 634.61 | 604.03 | 562.20 | 568.00 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 634.83 | 634.61 | 604.03 | 562.20 | 568.00 |
| Dividend / Share (Rs.) | 125.00 | 140.00 | 130.00 | 150.00 | 115.00 |
| Revenue From Operations / Share (Rs.) | 1219.02 | 1136.57 | 1144.70 | 1054.43 | 949.06 |
| PBDIT / Share (Rs.) | 180.24 | 230.51 | 220.07 | 192.81 | 194.99 |
| PBIT / Share (Rs.) | 161.34 | 214.03 | 202.36 | 178.44 | 178.62 |
| PBT / Share (Rs.) | 157.55 | 209.66 | 220.51 | 188.60 | 176.95 |
| Net Profit / Share (Rs.) | 126.50 | 164.92 | 168.86 | 143.72 | 109.82 |
| PBDIT Margin (%) | 14.78 | 20.28 | 19.22 | 18.28 | 20.54 |
| PBIT Margin (%) | 13.23 | 18.83 | 17.67 | 16.92 | 18.82 |
| PBT Margin (%) | 12.92 | 18.44 | 19.26 | 17.88 | 18.64 |
| Net Profit Margin (%) | 10.37 | 14.51 | 14.75 | 13.63 | 11.57 |
| Return on Networth / Equity (%) | 19.92 | 25.98 | 27.95 | 25.56 | 19.33 |
| Return on Capital Employeed (%) | 23.96 | 32.03 | 31.31 | 29.74 | 30.05 |
| Return On Assets (%) | 10.82 | 16.10 | 16.20 | 14.82 | 11.63 |
| Asset Turnover Ratio (%) | 1.11 | 1.10 | 1.14 | 1.10 | 1.06 |
| Current Ratio (X) | 2.01 | 2.44 | 2.19 | 2.15 | 2.26 |
| Quick Ratio (X) | 0.94 | 1.48 | 1.18 | 1.24 | 1.41 |
| Inventory Turnover Ratio (X) | 2.80 | 1.48 | 1.39 | 1.82 | 2.17 |
| Dividend Payout Ratio (NP) (%) | 98.90 | 81.93 | 74.09 | 104.47 | 104.82 |
| Dividend Payout Ratio (CP) (%) | 86.04 | 74.48 | 67.06 | 94.98 | 91.22 |
| Earning Retention Ratio (%) | 1.10 | 18.07 | 25.91 | -4.47 | -4.82 |
| Cash Earning Retention Ratio (%) | 13.96 | 25.52 | 32.94 | 5.02 | 8.78 |
| Interest Coverage Ratio (X) | 47.61 | 52.81 | 44.31 | 67.11 | 69.48 |
| Interest Coverage Ratio (Post Tax) (X) | 34.41 | 38.78 | 30.35 | 46.49 | 39.73 |
| Enterprise Value (Cr.) | 21230.10 | 22377.29 | 17307.30 | 21584.03 | 22612.20 |
| EV / Net Operating Revenue (X) | 3.88 | 4.38 | 3.37 | 4.56 | 5.31 |
| EV / EBITDA (X) | 26.23 | 21.62 | 17.52 | 24.93 | 25.83 |
| MarketCap / Net Operating Revenue (X) | 4.04 | 4.61 | 3.54 | 4.73 | 5.59 |
| Retention Ratios (%) | 1.09 | 18.06 | 25.90 | -4.47 | -4.82 |
| Price / BV (X) | 7.76 | 8.26 | 6.70 | 8.86 | 9.34 |
| Price / Net Operating Revenue (X) | 4.04 | 4.61 | 3.54 | 4.73 | 5.59 |
| EarningsYield | 0.02 | 0.03 | 0.04 | 0.02 | 0.02 |
After reviewing the key financial ratios for Bayer CropScience Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 126.38. This value is within the healthy range. It has decreased from 164.77 (Mar 24) to 126.38, marking a decrease of 38.39.
- For Diluted EPS (Rs.), as of Mar 25, the value is 126.38. This value is within the healthy range. It has decreased from 164.77 (Mar 24) to 126.38, marking a decrease of 38.39.
- For Cash EPS (Rs.), as of Mar 25, the value is 145.41. This value is within the healthy range. It has decreased from 181.40 (Mar 24) to 145.41, marking a decrease of 35.99.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 634.83. It has increased from 634.61 (Mar 24) to 634.83, marking an increase of 0.22.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 634.83. It has increased from 634.61 (Mar 24) to 634.83, marking an increase of 0.22.
- For Dividend / Share (Rs.), as of Mar 25, the value is 125.00. This value exceeds the healthy maximum of 3. It has decreased from 140.00 (Mar 24) to 125.00, marking a decrease of 15.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,219.02. It has increased from 1,136.57 (Mar 24) to 1,219.02, marking an increase of 82.45.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 180.24. This value is within the healthy range. It has decreased from 230.51 (Mar 24) to 180.24, marking a decrease of 50.27.
- For PBIT / Share (Rs.), as of Mar 25, the value is 161.34. This value is within the healthy range. It has decreased from 214.03 (Mar 24) to 161.34, marking a decrease of 52.69.
- For PBT / Share (Rs.), as of Mar 25, the value is 157.55. This value is within the healthy range. It has decreased from 209.66 (Mar 24) to 157.55, marking a decrease of 52.11.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 126.50. This value is within the healthy range. It has decreased from 164.92 (Mar 24) to 126.50, marking a decrease of 38.42.
- For PBDIT Margin (%), as of Mar 25, the value is 14.78. This value is within the healthy range. It has decreased from 20.28 (Mar 24) to 14.78, marking a decrease of 5.50.
- For PBIT Margin (%), as of Mar 25, the value is 13.23. This value is within the healthy range. It has decreased from 18.83 (Mar 24) to 13.23, marking a decrease of 5.60.
- For PBT Margin (%), as of Mar 25, the value is 12.92. This value is within the healthy range. It has decreased from 18.44 (Mar 24) to 12.92, marking a decrease of 5.52.
- For Net Profit Margin (%), as of Mar 25, the value is 10.37. This value exceeds the healthy maximum of 10. It has decreased from 14.51 (Mar 24) to 10.37, marking a decrease of 4.14.
- For Return on Networth / Equity (%), as of Mar 25, the value is 19.92. This value is within the healthy range. It has decreased from 25.98 (Mar 24) to 19.92, marking a decrease of 6.06.
- For Return on Capital Employeed (%), as of Mar 25, the value is 23.96. This value is within the healthy range. It has decreased from 32.03 (Mar 24) to 23.96, marking a decrease of 8.07.
- For Return On Assets (%), as of Mar 25, the value is 10.82. This value is within the healthy range. It has decreased from 16.10 (Mar 24) to 10.82, marking a decrease of 5.28.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.11. It has increased from 1.10 (Mar 24) to 1.11, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 2.01. This value is within the healthy range. It has decreased from 2.44 (Mar 24) to 2.01, marking a decrease of 0.43.
- For Quick Ratio (X), as of Mar 25, the value is 0.94. This value is below the healthy minimum of 1. It has decreased from 1.48 (Mar 24) to 0.94, marking a decrease of 0.54.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.80. This value is below the healthy minimum of 4. It has increased from 1.48 (Mar 24) to 2.80, marking an increase of 1.32.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 98.90. This value exceeds the healthy maximum of 50. It has increased from 81.93 (Mar 24) to 98.90, marking an increase of 16.97.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 86.04. This value exceeds the healthy maximum of 50. It has increased from 74.48 (Mar 24) to 86.04, marking an increase of 11.56.
- For Earning Retention Ratio (%), as of Mar 25, the value is 1.10. This value is below the healthy minimum of 40. It has decreased from 18.07 (Mar 24) to 1.10, marking a decrease of 16.97.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 13.96. This value is below the healthy minimum of 40. It has decreased from 25.52 (Mar 24) to 13.96, marking a decrease of 11.56.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 47.61. This value is within the healthy range. It has decreased from 52.81 (Mar 24) to 47.61, marking a decrease of 5.20.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 34.41. This value is within the healthy range. It has decreased from 38.78 (Mar 24) to 34.41, marking a decrease of 4.37.
- For Enterprise Value (Cr.), as of Mar 25, the value is 21,230.10. It has decreased from 22,377.29 (Mar 24) to 21,230.10, marking a decrease of 1,147.19.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.88. This value exceeds the healthy maximum of 3. It has decreased from 4.38 (Mar 24) to 3.88, marking a decrease of 0.50.
- For EV / EBITDA (X), as of Mar 25, the value is 26.23. This value exceeds the healthy maximum of 15. It has increased from 21.62 (Mar 24) to 26.23, marking an increase of 4.61.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.04. This value exceeds the healthy maximum of 3. It has decreased from 4.61 (Mar 24) to 4.04, marking a decrease of 0.57.
- For Retention Ratios (%), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 30. It has decreased from 18.06 (Mar 24) to 1.09, marking a decrease of 16.97.
- For Price / BV (X), as of Mar 25, the value is 7.76. This value exceeds the healthy maximum of 3. It has decreased from 8.26 (Mar 24) to 7.76, marking a decrease of 0.50.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.04. This value exceeds the healthy maximum of 3. It has decreased from 4.61 (Mar 24) to 4.04, marking a decrease of 0.57.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bayer CropScience Ltd:
- Net Profit Margin: 10.37%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 23.96% (Industry Average ROCE: 15.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 19.92% (Industry Average ROE: 19.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 34.41
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.94
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 33.6 (Industry average Stock P/E: 32.33)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.37%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Agro Chemicals/Pesticides | Bayer House, Central Avenue, Mumbai Maharashtra 400607 | ir_bcsl@bayer.com http://www.bayer.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Pankaj Ramanbhai Patel | Chairman & Ind.Dire (Non-Exe) |
| Mr. Simon Thorsten Wiebusch | Vice Chairman & Mng.Director |
| Mr. Vinit Rajesh Jindal | Executive Director & CFO |
| Dr. Thomas Hoffmann | Non Exe.Non Ind.Director |
| Ms. Jana Marlen Ackermann | Non Exe.Non Ind.Director |
| Ms. Radhika Rajan | Ind. Non-Executive Director |
| Mr. Sekhar Natarajan | Ind. Non-Executive Director |
| Mr. Sanjiv Rangrass | Ind. Non-Executive Director |